Background: Thromboelastography (TEG) has become the standard of care in liver-transplant surgery to identify real-time abnormalities in the coagulation cascade. To our knowledge, no studies have been performed to measure the intrasubject reproducibility of TEG parameters in cirrhotic patients.
(PTT), fibrinogen values, and platelet counts are indicative of general liver dysfunction, rather than being predictive of bleeding risk. 1 In clinical scenarios such as liver transplantation, in which the analysis of thecoagulation status of a patient can have immediate clinical implications, whole blood global viscoelastic tests (VETs), which more accurately indicate coagulation status, have become the standard of care to guide blood product use. 2 The thromboelastography (TEG) assay measures changes that occur during hemostasis. 3 Information provided by the graphical tracing of the TEG results can be used to determine abnormalities in specific parts of the coagulation cascade and then to determine the appropriate transfusion intervention.
The TEG assay has been used effectively during liver transplantation as a point-of-care (POC) instrument to guide therapy with blood products. 4 It has also been shown to reduce transfusion requirements in patients with cirrhosis who are scheduled for invasive procedures. 5 Because the TEG assay has been applied in the clinical setting, we sought to establish its intrasubject variability in clinically stable cirrhosis and added measurements of clot strength (functional fibrinogen [FF] ) to determine which, if any, parameters might serve as a baseline by which to measure future fluctuations. In addition, we sought to investigate hemostasis in patients with cirrhosis by comparing values obtained by TEG testing to conventional coagulation parameters, such as PT/INR, PTT, and platelet count. The study was approved by the institutional review board of Einstein Medical Center, Philadelpia, PA.
Materials and Methods
Sixty-five consecutive adult patients who were seen in the hepatology practice of the Einstein Medical Center in Philadelphia, PA, during the 3-month enrollment period were screened for the study. 
Collection of Blood Specimens
After written informed consent, blood was obtained using a venipuncture with a 20-gauge needle into the Vacutainer (Becton, Dickinson and Company). Blood was obtained in 2 tubes, 1 containing citrate and the other containing heparin. We also simultaneously obtained blood for laboratory measurement of conventional coagulation tests and a complete blood count. The specimens were processed within 30 minutes of collection. We collected the second blood specimen after a period of 1 hour.
TEG Testing
We performed TEG testing using a 2-channel system provided by the manufacturer (TEG 5000 Thrombelastograph Hemostasis Analyzer system, Haemonetics Corporation).
For TEG testing with kaolin as the activator, we measured reaction time (R value), which represents the time from the start of the test to initial fibrin formation (amplitude of 2 mm). Second, we measured the K value, which is defined as the time between the TEG tracing reaching 2 mm and the tracing reaching 20 mm (representing the speed of clot formation). Third, we measured alpha (α), which is the angle between the line representing the center of the TEG tracing and the line tangential to the developing TEG tracing; this process measures the rate of clot formation. Fourth, we measured the maximum amplitude (MA), which is a reflection of clot strength that is made up of platelets and fibrinogen. The final measurement was of Ly 30, or percent of clot lysis after 30 minutes, which reflects action in the fibrinolytic pathway. 6 The R time represents a period of initial fibrin formation. Clot kinetics are represented by the angle (rate of clot formation) and K time (speed to reach a specified level of clot strength). Clot strength is demonstrated by the MA. To further identify different factors that contribute to clot strength, we also measured FF using TEG (FF TEG; Hemonetics Corporation). FF TEG values have been shown to correlate with fibrinogen levels, as measured by the Clauss method, in patients undergoing liver transplantation. 7 In the TEG FF assay, 500 μL of citrated blood was added to a FF reagent vial. The vial was carefully mixed by inversion 5 times before loading the activated blood (340 μL) into the TEG cup containing CaCl2 (20 μL). This procedure was performed per manufacturer instructions.
FF directly measures the contribution of fibrinogen to clot strength. The FF reagent activates the extrinsic pathway using tissue factor and inhibits platelet aggregation using a platelet inhibitor that binds to the platelet glycoprotein IIb/ IIIa receptors (abciximab). Consequently, the ability of platelets to interact with fibrin and von Willebrand factor, is fully inhibited, thereby excluding the contribution of platelets to clot strength (ie, MAp). As a result, the only contribution to clot strength is from Fibrinogen. Hence, we measure only the MA of fibrinogen (MAf) as a contributor to clot strength.
Conventional Coagulation Parameters and Clinical Data
PT with INR, activated PTT and fibrinogen values were studied simultaneously with the TEG. In addition, a CBC, creatinine level, and total bilirubin levels were measured in all patients. These values were then used to calculate the Model for End-Stage Liver Disease (MELD) and Child-Pugh scores. 
Results
We enrolled 30 patients in the study. For determination of intrasubject reproducibility (test-retest reliability), 25 patients were studied; 5 were excluded due to technical issues while performing the test. The demographic and clinical characteristics of the 25 patients we studied are reported in Table 1 . Laboratory characteristics are cited in Table 2 . The median age of the patients was 61 years; 15 of the patients were male. The most common cause of cirrhosis was hepatitis C virus (HCV), and the median MELD score was 9.
An intraclass correlation (ICC) statistic ( Table 3 ) was derived to assess reproducibility of the test. All parameters showed an excellent correlation except the R time which showed moderate correlation.
All patients in the study had clinically stable health, including 7 patients with ascites and 10 patients with a history of esophageal varices. The TEG parameters among these patients were normal; the test results showed normal clot formation. None of the patients demonstrated abnormal clot lysis times.
Spearman correlation coefficients between TEG and conventional values are reported in important POC information regarding rate, strength, and stability of clot formation. It is used to guide transfusion of blood products in liver transplantation, as well as cardiac and trauma surgery. By obtaining real-time information about clot formation during operations, use of blood products has been dramatically reduced. 2 Patients with cirrhosis have an altered coagulation milieu, and there are questions among health care professionals regarding the potential role of TEG testing in the management of stable liver disease. Our evolving understanding is that patients with cirrhosis can have normal hemostasis or may even have prothrombotic characteristics. These observations raise questions regarding the ability to accurately predict coagulation defects and how to use blood products most judiciously, given the conventional coagulation tests that are currently available. 8 Further, in patients with liver disease, the INR, as calculated currently (using the International Sensitivity Index [ISI] for patients taking warfarin) may not be applicable. 9 De Pietri et al 5 showed that using a TEG to guide preprocedure transfusion strategies in patients with cirrhosis and coagulopathic manifestations led to a significantly lower use of blood products without an increase in bleeding complications. A caveat to the study was that the reproducibility of the TEG was not studied. When used in an emergency setting such as a transplant, blood products can be transfused as soon as the test results are obtained. However, to expand the use of the TEG in a nonemergency setting, the consistency of values measured by the TEG or its reproducibility becomes critical.
Our study assessed the consistency in TEG values obtained over time and compared these findings with conventional coagulation parameters. All TEG values showed high correlation when measured 1 hour apart. These findings prove that the TEG is a reliable means of measuring clot formation dynamics in this patient population.
The MA showed a high correlation with platelets and fibrinogen, both of which are essential in the final step of clot formation. The aPTT and K time also showed correlation, whereas while the PT 
